CD33 and neoplasm: Due to the consumption of GO in the peripheral blood and poor ability to enter the bone marrow, high levels of CD33 tumor burden in the peripheral blood and high levels of circulating CD33 confer resistance to the medication and are linked with weaker responses [22].